CGRP & Migraine Research
Explore migraine research on CGRP biology, CGRP-targeted treatments, efficacy, safety and emerging therapeutics.
-
Cost-utility analysis of erenumab preventive treatment for chronic migraine in China.
Authors: Wang L, Zhu M, Hu Q, Lou S, Wu M Other / unclear
This study looked at the cost-effectiveness of erenumab for chronic migraine in China. Erenumab is a preventive treatment given as an injection every four weeks. Researchers compared its effects to no preventive…
-
Time Course of Rimegepant Effect for Acute Treatment of Migraine in Adults Unsuitable for Triptans: Exploratory Endpoints from a Phase 4, Randomized, Double-Blind, Placebo-Controlled Study.
Authors: Lanteri-Minet M, Smith T, Nalpas C, Ramirez LM, Thiry A Clinical trial
A recent study explored the effects of rimegepant for treating migraines. This trial focused on adults who cannot use triptans. Participants received a single dose of rimegepant 75 mg or a placebo. The study measured…
-
Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies.
Authors: Pellesi L, Yangjeh A, Hajjaj I, Onan D, Waliszewska-Prosół M Systematic review / meta-analysis
Anti-CGRP therapies are important for preventing migraines. This study looked at how long patients stay on these treatments. It also examined why some patients stop using them. Researchers gathered data from various…
-
Comparative efficacy of AAC and ibuprofen versus lasmiditan, ubrogepant, and rimegepant for the acute treatment of episodic migraine in adults: a systematic review and network meta-analysis.
Authors: Mitra A, Franks B, Petruschke R, Dhiman A, Bansal N Systematic review / meta-analysis
This study compares the effectiveness of over-the-counter (OTC) migraine treatments with newer prescription medications. Researchers analyzed data from 25 randomized controlled trials (RCTs). They focused on how well…
-
Anti-calcitonin gene-related peptide treatments in women's health: Gaps and clinical evidence in menstrual-related migraine, pregnancy, lactation, and hormonal contraception: A narrative review.
Authors: Pejic J, Anandakumar J, Marks LA, Halker Singh RB, Ailani J Case report / case series
This research paper reviews the use of anti-calcitonin gene-related peptide (CGRP) treatments for women. It focuses on menstrual-related migraines and their impact during pregnancy, lactation, and while using…
-
Efficacy and Safety of Erenumab in the Preventive and Therapeutic Treatment of Patients Suffering From Migraine.
Authors: Patel Y, Panchal S, Patel A, Parker V, Rathod HS Systematic review / meta-analysis
Erenumab is a new medication aimed at preventing migraines. It works by blocking a specific receptor involved in migraine attacks. This study reviewed six clinical trials with 3,403 participants. Researchers looked…
-
Improvements in Patient-Reported Outcome Measures Through 64 Weeks' Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension.
Authors: Lipton RB, Buse DC, Martin VT, Semel D, Cappelleri JC Clinical trial
In a recent study, researchers examined how rimegepant improves migraine treatment over 64 weeks. This involved 741 participants, mostly women, aged about 41 years. The study had two phases: a 12-week double-blind…
-
Effectiveness of atogepant in migraine with and without medication overuse: Pooled real-world analysis of two independent clinical cohorts.
Authors: De Luca M, Ferraù L, Adragna MS, Cafarchio A, Grugno R Observational study
This study looked at how effective atogepant is for treating migraines. Atogepant is taken once daily at a dose of 60 mg. Researchers combined data from two groups of patients with migraines. One group followed up…
-
Emerging pharmacological targets in migraine therapy: CGRP and beyond.
Authors: Atraszkiewicz D, Dahiya D Review
Migraine is a common and challenging neurological disorder affecting many people. Current treatments often rely on repurposed medications, leading to frequent treatment failures. Research shows that migraine is not…
-
Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine-Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine.
Authors: Lipton RB, Gandhi P, Gantenbein AR, Dabruzzo B, Carr K Clinical trial
Atogepant is a new treatment for preventing migraines. This study looked at how it helps improve daily activities. Researchers analyzed data from three large clinical trials. They focused on patient-reported outcomes…
-
Beyond pain relief: rethinking sleep outcomes in CGRP-targeted migraine therapy.
Authors: Daou M, Lee-Iannotti JK, Robblee J Review
CGRP-targeted therapies have changed how we treat migraines, but their impact on sleep isn’t fully clear. This review looks at recent studies on sleep outcomes with these therapies. These treatments include…
-
Resistance training for migraine in females: mechanistic review of hormonal, CGRP, autonomic, vascular and nociceptive pathways.
Authors: Tornero-Aguilera JF, Muñoz-López M, Casas-Gómez M, Zabaleta-Korta A, López-Gil JF Guideline / consensus
Resistance training (RT) can help reduce migraine frequency in women. Women are more affected by migraines than men, especially after puberty. This is linked to hormonal changes, particularly estrogen levels. The…
-
Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease.
Authors: Bellotti A, Noseda R, Masciullo R, Staedler C, Gobbi C Observational study
CGRP pathway inhibitors are effective treatments for preventing migraines. This study focused on their long-term safety in patients with previous cerebrovascular or cardiovascular diseases. Researchers analyzed data…
-
Depressive and anxiety symptoms during CGRP-targeted migraine prevention: A systematic review and meta-analysis.
Authors: Al-Sayegh Z, Al-Khazali S, Al-Khazali HM, Christensen RH, Videbech P Systematic review / meta-analysis
Migraine often occurs alongside depression and anxiety, worsening patients' overall health. This study looked at how CGRP-targeted therapies affect these mental health symptoms. CGRP-targeted treatments are effective…
-
Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCE.
Authors: Lipton RB, Goadsby PJ, Pozo-Rosich P, Urani A, Lambru G Observational study
This study looked at how well rimegepant works for treating migraines. Researchers focused on patients using different preventive medications. The study involved participants in the United States who had 3-14…
-
Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis.
Authors: Ibrahim T, Burhan M, Bin Shafiq S, Wajahat A, Sanaullah O Systematic review / meta-analysis
Fremanezumab is a new treatment for preventing episodic migraines. This research reviewed its effectiveness and safety through a systematic analysis. The study included four clinical trials with 1,764 participants…
-
Retrospective Review of Dual CGRP-Targeted Regimens for Acute and Preventive Treatment of Migraines in a Veteran Population.
Authors: Forrest A, Billow D, Martin A Clinical trial
A recent study examined the safety and effectiveness of dual CGRP-targeted treatments for migraines. Researchers focused on patients who used both preventive and acute CGRP medications. The study included 89…
-
Anti-CGRP Monoclonal Antibodies in Chronic Migraine: A Position Statement of the Brazilian Academy of Headache and Orofacial Pain.
Authors: Krymchantowski A, Júnior HMDS, Silva-Néto RP, Jevoux C, Costa ALC Guideline / consensus
Chronic migraine (CM) is a serious condition affecting many people. It often comes with other health issues and is hard to treat. Recent treatments include anti-calcitonin gene-related peptide (CGRP) monoclonal…
-
Atogepant modulates brain connectivity in episodic migraine: a longitudinal exploratory fMRI study.
Authors: Montisano DA, Fedeli D, Demichelis G, Ciullo G, Medina Carrion JP Observational study
Episodic migraine (EM) is a common and debilitating condition affecting many people. Recent treatments have focused on a substance called CGRP, which plays a role in migraines. Atogepant is a new oral medication that…
-
The Estrogen-CGRP Axis in Migraine: Neuroimmune Mechanisms, Sex Differences, and Therapeutic Implications.
Authors: Dağ MY, Ölçüoğlu R Review
Migraine is a common disorder that affects many people, especially women. Research shows that estrogen and calcitonin gene-related peptide (CGRP) may play key roles. These two factors interact and influence how…